Biophytis reports H1 2026 results, advances BIO101 obesity and sarcopenia plans
The Paris biotech detailed progress on a planned obesity trial and a Hong Kong joint venture for sarcopenia, while extending its projected cash runway into early 2028.
Biophytis SA reported its first-half 2026 financial results and provided a strategy update on October 30, 2026, according to a Form 6-K filed with the SEC. CEO Stanislas Veillet said the first half of 2026 saw significant progress in the development of BIO101, with the establishment of a joint venture in Hong Kong and continued preparations for clinical programs in sarcopenia and obesity, and that since the end of the first half, the OBA study received authorization in Brazil following earlier authorizations in Europe and the United States, while the company also extended its expected cash runway through the first quarter of 2028.1
On the obesity program, Biophytis is readying a Phase 2 trial called "OBA" that will test BIO101 alongside GLP-1 therapies, aiming to preserve muscle strength and mobility during weight loss1. The company said the protocol has been amended to assess the rebound effect following discontinuation of GLP-1 treatment1. The study is now fully funded following the September capital increase, and recruitment of the first patient is expected in the first quarter of 20271. The program will run in the United States, Europe and Brazil, supported by partners including Blanver, FarmaVax, and the EMBRAPII unit at the Federal University of Minas Gerais, which is providing undisclosed non-dilutive funding1.
For sarcopenia, Biophytis is preparing an international Phase 3 study called SARA-31. To support development and commercialization of BIO101 in Asia, the company formed a Hong Kong joint venture with Asian partners during the first half of 2026, carrying a funding commitment of up to $20 million over three years, with next steps including IP contribution, a licensing agreement, and an initial $3 million payment subject to administrative approvals.1
On finances, after the reporting period Biophytis raised cash through a €5.3 million capital increase, €2.5 million from warrant exercises, and a €1.2 million drawdown under its Hexagon facility, bringing cash to €8.9 million as of September 11, 2026.1 The company said it believes it has sufficient resources to fund operations through the first quarter of 2028, based on current plans including debt reduction and Board assumptions reviewed October 26, 2026.1
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.